Business Structuring for European Pharmaceutical Supplier with Swiss Holding Setup

We advised a client supplying generic pharmaceuticals in several European countries on matters of business structuring. Our approach was framed within broader legal and regulatory support parameters to ensure compliance across multiple jurisdictions and minimize exposure to future cross-border legal complications. The main objective was to preserve ownership anonymity and leverage the advantages of the Swiss corporate law and tax system when consolidating companies into a holding structure. This also allowed us to integrate strategies commonly applied in investor relations advisory, aligning the structure for long-term governance clarity and ownership neutrality.

The client also expressed concerns about the future distribution of his business among his children in the event of his death and requested the creation of a structure that would accommodate these wishes. e addressed these succession priorities while accounting for family business continuity, a consideration highlighted in the Risk Monitor 2023 as a potential vulnerability in privately held mid-sized firms.

After analyzing the case and providing consultations, we fulfilled his additional instructions by establishing the holding company. The resulting framework also reflects best practices in corporate restructuring and relocation support, ensuring tax-efficient scalability and inheritance alignment.
This case also illustrates parallels with structural optimizations in other regulated fields, such as the IT sector legal reorganization, where operational resilience and privacy remain central goals.